These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
209 related articles for article (PubMed ID: 32487090)
1. The adaptive immune and immune checkpoint landscape of neoadjuvant treated esophageal adenocarcinoma using digital pathology quantitation. Humphries MP; Craig SG; Kacprzyk R; Fisher NC; Bingham V; McQuaid S; Murray GI; McManus D; Turkington RC; James J; Salto-Tellez M BMC Cancer; 2020 Jun; 20(1):500. PubMed ID: 32487090 [TBL] [Abstract][Full Text] [Related]
2. A study of the immune infiltrate and patient outcomes in esophageal cancer. Conroy MJ; Kennedy SA; Doyle SL; Hayes B; Kavanagh M; van der Stok EP; O'Sullivan K; Cathcart MC; Reynolds JV; Lysaght J Carcinogenesis; 2021 Apr; 42(3):395-404. PubMed ID: 32940666 [TBL] [Abstract][Full Text] [Related]
3. Tumor-immune landscape patterns before and after chemoradiation in resectable esophageal adenocarcinomas. Soeratram TT; Creemers A; Meijer SL; de Boer OJ; Vos W; Hooijer GK; van Berge Henegouwen MI; Hulshof MC; Bergman JJ; Lei M; Bijlsma MF; Ylstra B; van Grieken NC; van Laarhoven HW J Pathol; 2022 Mar; 256(3):282-296. PubMed ID: 34743329 [TBL] [Abstract][Full Text] [Related]
4. Tumor-Infiltrating Immune Cells and PD-L1 as Prognostic Biomarkers in Primary Esophageal Small Cell Carcinoma. Wu X; Ke X; Ni Y; Kuang L; Zhang F; Lin Y; Lin W; Xiong X; Huang H; Lin X; Zhang H J Immunol Res; 2020; 2020():8884683. PubMed ID: 33457428 [TBL] [Abstract][Full Text] [Related]
5. High CD8 Koemans WJ; van Dieren JM; van den Berg JG; Meijer GA; Snaebjornsson P; Chalabi M; Lecot F; Riedl R; Krijgsman O; Hofland I; Broeks A; Voncken FEM; Peppelenbosch MP; Sosef MN; van Sandick JW; Kodach LL Histopathology; 2021 Aug; 79(2):238-251. PubMed ID: 33660299 [TBL] [Abstract][Full Text] [Related]
6. Elevated X-linked inhibitor of apoptosis protein (XIAP) expression uncovers detrimental prognosis in subgroups of neoadjuvant treated and T-cell rich esophageal adenocarcinoma. Schiffmann LM; Göbel H; Löser H; Schorn F; Werthenbach JP; Fuchs HF; Plum PS; Bludau M; Zander T; Schröder W; Bruns CJ; Kashkar H; Quaas A; Gebauer F BMC Cancer; 2019 May; 19(1):531. PubMed ID: 31151416 [TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of IgG4+ plasma cell infiltrates following neoadjuvant chemoradiation therapy for esophageal adenocarcinoma. Yakirevich E; Lu S; Allen D; Mangray S; Fanion JR; Lombardo KA; Safran H; Resnick MB Hum Pathol; 2017 Aug; 66():126-135. PubMed ID: 28666927 [TBL] [Abstract][Full Text] [Related]
8. Tumour infiltrating lymphocytes correlate with improved survival in patients with oesophageal adenocarcinoma. Noble F; Mellows T; McCormick Matthews LH; Bateman AC; Harris S; Underwood TJ; Byrne JP; Bailey IS; Sharland DM; Kelly JJ; Primrose JN; Sahota SS; Bateman AR; Thomas GJ; Ottensmeier CH Cancer Immunol Immunother; 2016 Jun; 65(6):651-62. PubMed ID: 27020682 [TBL] [Abstract][Full Text] [Related]
9. The Impact of Esophageal Oncological Surgery on Perioperative Immune Function; Implications for Adjuvant Immune Checkpoint Inhibition. Donlon NE; Davern M; Sheppard AD; O'Connell F; Dunne MR; Hayes C; Mylod E; Ramjit S; Temperley H; Mac Lean M; Cotter G; Bhardwaj A; Butler C; Conroy MJ; O'Sullivan J; Ravi N; Donohoe CL; Reynolds JV; Lysaght J Front Immunol; 2022; 13():823225. PubMed ID: 35154142 [TBL] [Abstract][Full Text] [Related]
10. Programmed Death Ligand 1: A Step Toward Immunoscore for Esophageal Cancer. Hynes CF; Kwon DH; Vadlamudi C; Lofthus A; Iwamoto A; Chahine JJ; Desale S; Margolis M; Kallakury BV; Watson TJ; Haddad NG; Marshall MB Ann Thorac Surg; 2018 Oct; 106(4):1002-1007. PubMed ID: 29859152 [TBL] [Abstract][Full Text] [Related]
11. PD-L1 Expression, Tumor-infiltrating Lymphocytes, and Clinical Outcome in Patients With Surgically Resected Esophageal Cancer. Yagi T; Baba Y; Ishimoto T; Iwatsuki M; Miyamoto Y; Yoshida N; Watanabe M; Baba H Ann Surg; 2019 Mar; 269(3):471-478. PubMed ID: 29206673 [TBL] [Abstract][Full Text] [Related]
12. Indoleamine 2,3-Dioxygenase (IDO) Expression Is an Independent Prognostic Marker in Esophageal Adenocarcinoma. Loeser H; Kraemer M; Gebauer F; Bruns C; Schröder W; Zander T; Alakus H; Hoelscher A; Buettner R; Lohneis P; Quaas A J Immunol Res; 2020; 2020():2862647. PubMed ID: 33029538 [TBL] [Abstract][Full Text] [Related]
13. Paired whole exome and transcriptome analyses for the Immunogenomic changes during concurrent chemoradiotherapy in esophageal squamous cell carcinoma. Park S; Joung JG; Min YW; Nam JY; Ryu D; Oh D; Park WY; Lee SH; Choi Y; Ahn JS; Ahn MJ; Park K; Sun JM J Immunother Cancer; 2019 May; 7(1):128. PubMed ID: 31097034 [TBL] [Abstract][Full Text] [Related]
14. HLA-DR expression in tumor epithelium is an independent prognostic indicator in esophageal adenocarcinoma patients. Dunne MR; Michielsen AJ; O'Sullivan KE; Cathcart MC; Feighery R; Doyle B; Watson JA; O'Farrell NJ; Ravi N; Kay E; Reynolds JV; Ryan EJ; O'Sullivan J Cancer Immunol Immunother; 2017 Jul; 66(7):841-850. PubMed ID: 28315927 [TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of tumor-infiltrating immune cells and PD-L1 expression in esophageal squamous cell carcinoma. Jiang Y; Lo AWI; Wong A; Chen W; Wang Y; Lin L; Xu J Oncotarget; 2017 May; 8(18):30175-30189. PubMed ID: 28404915 [TBL] [Abstract][Full Text] [Related]
16. Distribution of tumor-infiltrating-T-lymphocytes and possible tumor-escape mechanisms avoiding immune cell attack in locally advanced adenocarcinomas of the esophagus. Schoemmel M; Loeser H; Kraemer M; Wagener-Ryczek S; Hillmer A; Bruns C; Thelen M; Schröder W; Zander T; Lechner A; Buettner R; Schlösser H; Gebauer F; Quaas A; Clin Transl Oncol; 2021 Aug; 23(8):1601-1610. PubMed ID: 33566304 [TBL] [Abstract][Full Text] [Related]
17. Exploring the immune microenvironment in small bowel adenocarcinoma using digital image analysis. Sidi FA; Bingham V; McQuaid S; Craig SG; Turkington RC; James JA; Humphries MP; Salto-Tellez M PLoS One; 2023; 18(8):e0289355. PubMed ID: 37527282 [TBL] [Abstract][Full Text] [Related]
18. Digital pathology-aided assessment of tumor-infiltrating T lymphocytes in advanced stage, HPV-negative head and neck tumors. de Ruiter EJ; de Roest RH; Brakenhoff RH; Leemans CR; de Bree R; Terhaard CHJ; Willems SM Cancer Immunol Immunother; 2020 Apr; 69(4):581-591. PubMed ID: 31980916 [TBL] [Abstract][Full Text] [Related]
19. The Dynamic and Transient Immune Microenvironment in Locally Advanced Esophageal Adenocarcinoma Post Chemoradiation. Kelly RJ; Zaidi AH; Smith MA; Omstead AN; Kosovec JE; Matsui D; Martin SA; DiCarlo C; Werts ED; Silverman JF; Wang DH; Jobe BA Ann Surg; 2018 Dec; 268(6):992-999. PubMed ID: 28806299 [TBL] [Abstract][Full Text] [Related]
20. High number of CD45RO+ tumor infiltrating lymphocytes is an independent prognostic factor in non-metastasized (stage I-IIA) esophageal adenocarcinoma. Rauser S; Langer R; Tschernitz S; Gais P; Jütting U; Feith M; Höfler H; Walch A BMC Cancer; 2010 Nov; 10():608. PubMed ID: 21054833 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]